Latest Clinic Expansion News

Page 1 of 3
Emyria has reported record quarterly revenue of approximately $1.42 million after opening its first Sydney Empax clinic and expanding national treatment capacity. The growth comes with $2.28 million in operating cash outflows and an estimated 2.08 quarters of funding at quarter-end.
Ada Torres
Ada Torres
29 Oct 2026
Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.
Ada Torres
Ada Torres
28 Oct 2026
Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.
Victor Sage
Victor Sage
9 Oct 2026
4DMedical delivered sharp growth in scans, sites and operating revenue as CT:VQ moved into commercial deployment across several global markets. But the company remains loss-making and its auditor issued a qualified opinion over the carrying value of goodwill and other intangible assets.
Victor Sage
Victor Sage
24 Sept 2026
Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.
Ada Torres
Ada Torres
8 Sept 2026
Optiscan Imaging has launched a 35-patient clinical trial in the US to test its InVue™ and InForm™ platforms in head and neck cancer surgery, aiming to bolster its FDA submissions later this year.
Ada Torres
Ada Torres
1 Sept 2026
Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.
Ada Torres
Ada Torres
27 Aug 2026
Amplia Therapeutics has teamed up with Eli Lilly to test its FAK inhibitor narmafotinib alongside Lilly’s KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer, marking a strategic expansion beyond pancreatic and ovarian cancers.
Ada Torres
Ada Torres
4 Aug 2026
Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.
Ada Torres
Ada Torres
29 July 2026
Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.
Ada Torres
Ada Torres
29 June 2026
Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.
Ada Torres
Ada Torres
24 June 2026
Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.
Ada Torres
Ada Torres
11 June 2026

Browse the archive

Full archive